TDI-6570

Overview

TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC 50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1 , blocks double-stranded DNA -induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases.

Application

Products | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Systemic Lupus Erythematosus | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Alzheimer's Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Cyclic GMP-AMP Synthase | Products > Signaling Pathways > STING

Product Information

• Catalog No.: HY-164288
• CAS No.: 2287331-29-5
• Molecular Formula: C14H14ClFN2O2
• Molecular Weight: 296.72
• Purity: 99.64%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source